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Clinical triala b s t r a c t
The maturity in our understanding of the genetics and the pathogenesis of disease in degenerative retinal
disorders has intersected in past years with a novel treatment paradigm in which a genetic intervention
may lead to sustained therapeutic beneﬁt, and in some cases even restoration of vision. Here, we review
this prospect of retinal gene therapy, discuss the enabling technologies that have led to ﬁrst-in-human
demonstrations of efﬁcacy and safety, and the road that led to this exciting point in time.
 2014 Elsevier Ltd. All rights reserved.1. Clinical success, in triplicate RPE65 protein (Ebrey & Koutalos, 2001). The re-converted 11-cis-1.1. Clinical success in Leber Congenital Amaurosis due to mutations in
RPE65
Three independent clinical trials for retinal pigment epithe-
lium-speciﬁc 65 kDa protein (RPE65) deﬁciency in 2008
(Bainbridge et al., 2008; Cideciyan et al., 2008; Hauswirth et al.,
2008; Maguire et al., 2008) have led to genuine excitement and
anticipation from both the scientiﬁc and lay communities towards
the treatment of recessive monogenetic disorders that cause vision
loss. Mutations in RPE65 leads to early onset vision loss within the
disease spectrum referred to as Leber Congenital Amaurosis (LCA).
LCA-RPE65 patients generally present with signiﬁcantly decreased
vision in the ﬁrst year of life, nystagmus, and fundus changes con-
sistent atrophy of the pigment epithelium. The RPE65 gene encodes
an isomerase protein that is expressed in the retinal pigment epi-
thelium (RPE) and is an essential player in the recycling pathway of
11-cis-retinal in the visual cycle. Brieﬂy, light activation of the
visual pigments (opsins) present in the outer segments of photore-
ceptors occurs after photon capture by the 11-cis-retinal chromo-
phore triggering an isomerization event that converts it to all-
trans-retinal and releases it from the visual pigment (reviewed in
Ebrey & Koutalos, 2001). Recovery of the visual cycle after light
stimulation is therefore dependent on the conversion, in the RPE,
of the chromophore from all-trans-retinal to 11-cis-retinal by theretinal chromophore will now travel back to the photoreceptors
outer segments and re-attached itself to the visual pigments
(Ebrey & Koutalos, 2001).
The ﬁrst effective intervention using adeno-associated virus
(AAV)-based gene therapy in an animal model of retinal dystrophy
caused by an RPE defect was done in the Briard dog model which
has a naturally occurring mutation in the RPE65 gene. AAV2/2
mediated gene transfer after subretinal injections shown signiﬁ-
cant morphological and functional rescue of photoreceptors and
therefore recovery of 11-cis-retinal recycling by the RPE cells
(Acland et al., 2001; Le Meur et al., 2007; Narfstrom et al., 2003;
Rolling et al., 2006). These studies showed functional ERG
improvement of around 20–30% of wildtype levels and signiﬁcant
improvements in behavioral-based vision tests, especially under
photopic conditions (Acland et al., 2001; Le Meur et al., 2007;
Rolling et al., 2006). They were also able to demonstrate stable
and long-term restoration of vision up to 4 years follow-up post-
treatment (Acland et al., 2005; Narfstrom et al., 2008). These initial
studies in a large animal model of RPE65 deﬁciency that mimicked
the human LCA condition so well provided great encouragement
and an ideal candidate to move a gene therapy platform for inher-
ited retinal dystrophies towards the clinic.
The reports of the early stage clinical trials for RPE65 deﬁciency
were encouraging and attested for both safety and efﬁcacy of the
transgene and the selected AAV2/2 vector delivery agent (reviewed
inMacLaren, 2009). Some of the differences between the three trials
include vector sequence and design, dose (ranging from 1.5  1010
to 1.5  1011 viral particles) and injected volume (ranging from
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trials but it is unclear if and how this affects the outcome (see
Hauswirth et al., 2008 for summary table of differences between
trials).
With over a hundred disease-causing mutations identiﬁed so
far in RPE65 (source: www.retina-international.org), it was unsur-
prising that all the initial and subsequent patients selected for the
trials presented a diverse group of mutations (Hauswirth et al.,
2008; Testa et al., 2013). Identical homozygous mutations was only
seen in two patients of the Maguire et al. (2008) trial (E102K) and
between one patient in the Hauswirth et al. (2008) and Bainbridge
et al. (2008) trials (Y368H). Even after these initial studies were
expanded (Jacobson et al., 2012; Maguire et al., 2009), the diversity
of both homozygote and compound mutations in the recruited
patients remained high. This has made it difﬁcult so far to correlate
speciﬁc mutations with visual improvement outcomes, therefore
studying the effects each mutation has on RPE65 function needs
to be an ongoing effort and run in parallel to clinical trial data.
Arguably the most signiﬁcant difference between these trials
that may have inﬂuenced outcome was the choice and design of
promoter driving RPE65 expression. Although all three trials used
the recombinant AAV2/2 vector (rAAV), Bainbridge et al. (2008)
used a human RPE65 promoter while both Maguire et al. (2008)
and Hauswirth et al. (2008) used a modiﬁed version of the ubiqui-
tous chicken b actin promoter referred to as CAG promoter
(Miyazaki et al., 1989). Other vector sequence and design differ-
ences include the addition of an optimized Kozak sequence in
Maguire et al. (2008) trial. Although the human RPE65 promoter
has a weaker expression pattern when compared to the CAG pro-
moter, it was shown to drive enough transgene expression to res-
cue the phenotype of both younger and older treated Briard dogs
(Annear et al., 2013; Le Meur et al., 2007; Rolling et al., 2006).
These preclinical studies showed that the human RPE65 promoter
was capable of driving RPE-speciﬁc expression of the transgene,
which was opted to be preferred in terms of safety in this study.
In contrast, a ubiquitous promoter like CAG with a non-speciﬁc cell
expression proﬁle could generate concerns about RPE65 expression
in cell types other than RPE and what effect this would have in the
recovery of the visual cycle. However, a ubiquitous promoter has
its advantages, offering a more robust and stronger expression
pattern.
The promoter choice in the RPE65 clinical trials could offer an
explanation for the differences seen between the reported out-
comes, and indeed, visual improvements were more robust from
the two trials that used the CAG promoter (Hauswirth et al., 2008;
Jacobson et al., 2012; Maguire et al., 2008, 2009). These included
improved visual acuity and pupil response, increased sensitivity
and in visual ﬁeld size and a ﬁxation shift in the extrafoveal treat-
ment in one patient (Hauswirth et al., 2008; Jacobson et al., 2012;
Maguire et al., 2008). Long-term follow up of these studies have
demonstrated that stability, safety and efﬁciency of treatment can
persist up to at least 3 years post-treatment (Jacobson et al., 2012;
Testa et al., 2013). However it remains debated whether these stud-
ies have been able to show an age-dependent effect of the treatment
since the two studies with larger patient cohorts including younger
aged patients have reached contradictory conclusions. In the ﬁrst
study Maguire et al. (2009) concludes that treatment at a younger
agedoes have an overall effect on improvedvisual function although
a later study conducted by Jacobson et al. (2012) shows no correla-
tion between age and treatment effect. The younger patients in the
ﬁrst study (Maguire et al., 2009) do indeed show a more consistent
improvement in visual sensitivity when compared to the older
group of patients where the results were more variable but this
could easily be explained by the heterogeneity of disease severity
caused by RPE65 deﬁciency, generating a complex and individualistrelationship between disease progression and age. Indeed, a few of
the older patients show a similar increase in sensitivity when com-
pared to the younger ones and the visual acuity measurements do
not seem to show an age-related correlation. Our conclusion from
these data at this early stage of the ﬁeld is that too many variables
(mutation-dependent or idiosyncratic progression of disease, vec-
tor, injection parameters, and endpoint measures) between these
studies and subjects are at play. That being said, our understanding
of disease pathology and the data from these studies indicate a
greater beneﬁt from intervention at an earlier stage of the disease
process, which is age-related.
Next, the hypothesis was challenged whether gene augmenta-
tion therapy in this form of LCA would stem degenerative pro-
cesses in the outer retina, and ultimately determine whether the
beneﬁt observed in these pivotal trials would be long-lived
(Cideciyan et al., 2013). In this study Cideciyan and colleagues
extensively and thoroughly analyzed the natural history of the dis-
ease using the patients enrolled in one of the initial trials. They
concluded that despite the treatment, disease progression and
photoreceptor degeneration remained unchanged and followed
the expected natural history (further reviewed in Cepko &
Vandenberghe, 2013). Surprisingly they also show that the stan-
dard binary hallmark of inherited retinal degenerations namely
combined dysfunction and degeneration of photoreceptor cells –
is different between humans and the main animal model used
for the pre-clinical studies of LCA, the Briard dog model. While in
humans, dysfunction and photoreceptor degeneration are timely
coupled, in dogs impaired visual function occurs well before any
degeneration is seen. The authors conclude that the accumulation
of certain changes by non-functional RPE65 contributes to the gen-
eration of a threshold or window where treatment needs to fall
within to have signiﬁcant impact on photoreceptors degeneration
and visual improvement. This indeed aligns well with another
study from Cideciyan et al. where they show that despite signiﬁ-
cant increase in visual sensitivity after RPE65 gene therapy in
humans, the kinetics of rod photoreceptors recovery is still
impaired and suboptimal (Cideciyan et al., 2009). While these
studies are thorough in their analysis, the bold and disappointing
conclusions have been critiqued and challenged (Cepko &
Vandenberghe, 2013; Wojno, Pierce, & Bennett, 2013). Indeed,
the small group sizes, the multitude of variables delineated above,
and the very early assessment of long-term beneﬁt within a slow
degenerative process make any deﬁnitive conclusion difﬁcult. For
these reasons the Cideciyan study (Cideciyan et al., 2013) had to
use a novel methodological approach, measuring the thickness of
photoreceptors outer nuclear layer (ONL) based on normalized
OCT data and age correction between species and degenerative
states, to generate a predictive slope of the natural history of
RPE65-LCA. However, this approach may have its limitations in
accurately modeling long-term progression and treatment effects
since only one disease parameter, ONL thickness, was taken into
consideration. Patients with RPE65-LCA usually present a highly
variable disease progression rate, demonstrated by the weak corre-
lation between age and ONL thickness seen in this study, which
only showed a more consistent and stepper correlation when
adjusted for age of onset (Cideciyan et al., 2013). More importantly,
their analyses did not account for the diversity in RPE65 genetic
lesions present in this patient cohort that could have helped to bet-
ter understand the effect of different mutations on disease
progression.
Nonetheless, these studies do emphasize the point that gene
augmentation therapy has an inherently delineated therapeutic
window between the earliest time intervention can be considered
and the point when degenerative processes cannot be reverted and
eventually therapeutic target cells are terminally atrophied.
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trial
Earlier this year we saw the publication of the results of another
phase I/II clinical trial for a different type of inherited retinal
degeneration (MacLaren et al., 2014). This trial focused on patients
with Choroideremia, an X-linked recessive disorder of the retina
and choroid due to the loss of function of the Rab escort protein-
1 (REP1). MacLaren and colleagues used an AAV2 expression cas-
sette with the same ubiquitous CAG promoter used in some of
the previous RPE65 trials (Jacobson et al., 2012; Maguire et al.,
2008) but interestingly, added a Woodchuck hepatitis virus post-
translational regulatory element (WPRE) downstream of the REP1
encoding gene (CHM) cDNA. This regulatory element acts as an
enhancer of AAV-mediated transgene expression (Loeb et al.,
1999) and although long established in preclinical research and
in a few other clinical gene therapy studies, had not been used pre-
viously in the clinic for retinal gene therapy approaches.
This study enrolled six patients with null mutations in the CHM
gene that received 1  1010 genome particles of AAV2.REP1 vector
in a volume of 0.1 ml (except for patient six which received 6  109
particles in 0.06 ml) that was injected subretinally and layered
under the fovea as a two-step procedure. At the six months fol-
low-up an increase in the point of maximal sensitivity in all treated
eyes was observed as well as improvement of mean retinal sensi-
tivity in ﬁve out of six treated eyes. Not surprisingly, the two
patients with the highest increase in mean sensitivity, although
had the smallest area of treatment, received the highest dose of
vector per mm2 of retina. Maximal and mean sensitivities mea-
surements were taken under mesopic light conditions and are
therefore more indicative of rod photoreceptor function but they
also report an increase in visual acuity in two of the treated eyes
which had the lowest visual acuity baselines. The remaining four
patients where no visual acuity improvement was reported also
showed no detrimental effects after the treatment which coupled
with their near normal visual acuity at baseline highlights the fact
that the procedure-related retinal detachment in the fairly healthy
macular and foveal area is not a concern in these patients as seen
in other gene therapy trials (Jacobson et al., 2012). This is also cor-
roborated by outer retina thickness measurements that remained
similar before and at six months post-treatment. One of the most
interesting results however was the shift in retinal ﬁxation points
in two patients towards the treated area, and in one case, com-
pletely bypassing a close by area of residual retina that had not
been exposed to the vector. This effect was also seen in one patient
treated in one of the RPE65 trials (Cideciyan et al., 2009) and pro-
vides hope for improvements in visual acuity and sensitivity even
after the fovea and/or macular regions have undergone extensive
and irreversible degeneration.
This is the ﬁrst report of a gene therapy approach targeted
towards gene augmentation in photoreceptor cells. It also shows
that vector administration in patients with near normal visual acu-
ity and retinal thickness is safe and does not cause any detrimental
effects after the detachment induced by the procedure. Due to the
slow degeneration rate of Choroideremia, the normal visual acuity
of four out of the six patients and the treatment occurring before a
clinically signiﬁcant retinal thinning, it remains to be seen whether
in this case gene therapy is capable of slowing down the progres-
sion of photoreceptor loss.
1.3. Other ongoing translational programs
1.3.1. AMD clinical trials
Age-Related Macular Degeneration (AMD) is the leading cause
of visual loss in adults in Western societies (Aleman et al., 2008).
Its etiology is complex and only in part genetic. Its pathogenesisis fascinating and only partially understood. Early stage AMD is
characterized by subretinal deposits called drusen and retinal pig-
ment epithelium (RPE) irregularities in the macula, and often
called dry AMD. This pathology leads most often to no or limited
vision loss in the affected areas of the retina. Later stages of this
disease however are clinically much more signiﬁcant, and lead to
presentations of either large macular areas of degeneration, often
referred to as Geographic Atrophy, or a disease characterized by
choroidal neovascularization (CNV) which results in exudative or
the wet form of AMD. Only for wet AMD a treatment is currently
available which requires repeat intravitreal injections of agonist
of Vascular Endothelial Growth Factor (VEGF) (Holz, Schmitz-
Valckenberg, & Fleckenstein, 2014). In order to overcome the need
for repeat injections, and improve on the peak and trough pharma-
cology of bolus injections, several groups have considered encod-
ing a VEGF antagonist in a gene therapy vector. Two groups,
Genzyme-Sanoﬁ and Avalanche (partnered with Lions Eye Institute
in Australia), are progressing this approach in the clinic. Both
groups are using a similarly designed vector based on AAV2 encod-
ing soluble forms of secreted ligands of VEGF derived from Flt-1.
The Avalanche-Lions Institute trial is using the sFlt1 gene, an alter-
natively spliced form of the Flt1 protein containing only the extra-
cellular domains (Kendall & Thomas, 1993), while the Genzyme-
Sanoﬁ trial has selected the sFLT01 gene which encodes a hybrid
molecule made of the second immunoglobulin (IgG)-like domain
of Flt-1 fused to a human IgG1 Fc through a polyglycine linker
(Pechan et al., 2009). The other major distinction between the
two efforts is the route of administration with the Genzyme group
proposing intravitreal vector delivery, and Avalanche subretinal.
Both studies are ongoing and expected to present results in the
near future.
Currently the only clinical trials for visual disorders using len-
tiviral vectors are being run by Oxford BioMedica UK Ltd. (Oxford,
UK) and one of them is to treat neovascular AMD by delivering two
angiostatic proteins, endostatin and angiostatin, to the eye. They
are using an equine infectious anemia virus (EIAV)-based lentiviral
gene therapy vector expressing both proteins called RetinoStat.
Long-term safety studies in non-human primates and rabbits have
shown that RetinoStat is well tolerated after subretinal injections,
generating only a mild and transient ocular inﬂammatory response
(Binley et al., 2012). They also show that biodistribution is
restricted to ocular structures and stable expression of both endo-
statin and angiostatin was observed up to six months in rabbit vit-
reous samples (Binley et al., 2012). The phase I clinical trial of
RetinoStat will initially test safety and bioactivity of the vector in
patients with advance neovascular AMD by assessing baseline
changes in size of choroidal neovascular lesions, subretinal and
intraretinal ﬂuid and best corrective visual acuity. This trial will
not only provide valuable information regarding the effects of
endostatin and angiostatin on AMD patients but also test the efﬁ-
cacy and safety of using lentiviral vectors to delivery gene augmen-
tation for visual disorders.1.3.2. Clinical trials for other inherited retinal degenerations
In addition to RetinoStat, Oxford BioMedica UK Ltd. also has two
more products which they are currently recruiting for clinical tri-
als, StarGen™ and UshStat, to treat Stargardt macular degenera-
tion and retinitis pigmentosa associated with Usher syndrome type
1B (USH1B), respectively. In line with the AMD trial, StarGen and
UshStat are also nonreplicating, nonhuman recombinant lentiviral
vectors based on EIAV. The choice of a lentiviral-based vector for
these two trials is explained by the size of the transgene to be sup-
plemented. In both disorders, the disease-causing mutations are
found in genes which exceed the maximum genetic load AAV-
based vectors are capable of packaging, therefore creating the need
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genomes).
StarGen expresses the large human photoreceptor-speciﬁc
adenosine triphosphate (ATP)-binding cassette transporter (ABCA4)
gene under the regulation of a constitutively active CMV promoter
and will be delivered subretinally to target rod and cone photore-
ceptors. Preclinical safety and biodistribution of StarGen was eval-
uated by Binley et al. (2013) in rabbits and macaques and shown to
have expression restricted to ocular tissues and no antibodies to
StarGen vector components was detected in macaque serum. How-
ever, they report that in three out of six rabbit tissue samples, vec-
tor DNA was detected in the optic nerve. This could indicate a
possible somewhat inefﬁcient targeting of retinal ganglion cells
suggesting a non-photoreceptor speciﬁc expression of their vector.
Factors like the ubiquitous CMV promoter, vector tropism in rabbit
ocular tissue and the nature of vesicular stomatitis virus envelope
used to pseudotype the vector particles could all play a part in
these results and it is still unclear whether this could negatively
impact on the clinical trial outcome.
UshStat will be used to treat progressive retinitis pigmentosa in
USH1B patients that have mutations in the gene encoding a myosin
motor protein, myosin VIIA (MYO7A). Preclinical proof of concept
studies in the shaker1 mouse model of USH1B, which carries a
mutated copy of the Myo7a gene, and in non-human primates
has shown that the UshStat vector, carrying a transgene cassette
composed of the human MYO7A gene under the control of a CMV
promoter, is capable of successfully transducing both mouse and
monkey retinas after subretinal injections (Zallocchi et al., 2014).
Furthermore, UshStat was able to prevent light-induced retinal
degeneration. Similar to what was reported with RetinoStat, a tran-
sient ocular inﬂammatory response was seen in monkeys but no
humoral antibody response to either the MYO7A transgene or vec-
tor components was found (Zallocchi et al., 2014). The results from
the clinical trials for both UshStat and StarGen will hopefully help
assess the long-term safety, tolerability and biological activity of
these vectors alongside treatment efﬁcacy and will be extremely
useful in evaluated the suitability of using a lentiviral-based plat-
form for retinal therapy of large genes.
In February 2014 yet another clinical trial was initiated and is
currently recruiting patients to test the efﬁcacy of AAV2/2-based
gene therapy for a mitochondrial disease, Leber hereditary optic
neuropathy (LHON), which due to mutations in the ND4 gene
causes degeneration of the retinal ganglion cells (RGC) and atrophy
of the optic nerve and therefore vision loss (reviewed in Cwerman-
Thibault et al., 2014). Led by the company Gensight, they will be
testing their main product, GS010, in a Phase 1 and 2 dose-escala-
tion trials to evaluate safety and tolerability proﬁle of their product
in LHON patients. The GS010 is an AAV2/2 based vector encoding
the mitochondrial NADH dehydrogenase 4 (ND4) gene and will
be delivered intravitreally to target the RGCs. Mitochondrial tar-
geting will be achieved by the fusion of the optimized human
wild-type ND4 Open Reading Frame (ORF) to a COX10 fragment
which encodes a N-terminal mitochondrial targeting sequence
(MTS) plus additional residues to ensure MTS cleavage afterwards
(Ellouze et al., 2008). Adding to the Genzyme/Sanoﬁ AMD trial, this
will be another effort towards intravitreally-delivered AAV2/2 to
provide gene augmentation under two different contexts and the
results will be eagerly awaited.2. Preclinical promise
2.1. Proof-of-concept in individual gene targeted therapies
These ﬁrst clinical trials were preceded by just over a decade of
intensive research therapeutic gene transfer to the retina whichsaw the efﬁciency of treatment in animal models grow exponen-
tially from the ﬁrst study done in the fast retinal degeneration
Pde6b-deﬁcient rd1 mouse model in 1997, showing only a minor
histological rescue of a few rows of photoreceptors (Jomary et al.,
1997), to some recent studies where near wild type level of func-
tional rescue has been reported (Carvalho et al., 2011; Dai et al.,
2014; Mihelec et al., 2011; Tan et al., 2009). The eye has several
features that make it an ideal candidate for gene therapy. It is a
small and immune-privileged organ where the blood–retina bar-
rier separates the ocular space from the blood supply reducing
therefore immune response to the vectors. The compartmentalized
and structured anatomy of the retina also allows for controlled and
localized delivery of relatively small amounts of the therapeutic
vector through a moderately easy surgical procedures and treat-
ment outcomes can be easily accessed by non-invasive methods
such as electroretinography (ERG) and optical coherence tomogra-
phy (OCT). The non-dividing character of both RPE and photorecep-
tors coupled with a plethora of inherited retinal diseases
encouraged the scientiﬁc community to take active steps towards
developing a gene therapy platform to treat vision loss.
The very ﬁrst efforts to target the retina for gene delivery were
done using replication-deﬁcient adenovirus and showed that the
RPE layer, but only a few individual photoreceptors, was quite per-
missive to viral transduction (Bennett et al., 1994). Further studies
tried to improve retinal transduction by adenovirus but only tem-
porary expression of the transgene was observed (Bennett et al.,
1996; Li et al., 1994; Mashhour et al., 1994). A few years later came
the ﬁrst report of efﬁcient retinal cell transduction by AAV-based
vectors, showing high RPE expression of the reporter gene by
28 days post-injection (Ali et al., 1996). Shortly after more perma-
nent and long-term retinal expression was observed when Miyoshi
et al. (1997) used an HIV-based lentiviral vector containing a green
ﬂuorescent protein (GFP) under the control of either the ubiquitous
CMV or photoreceptor-speciﬁc Rhodopsin promoter to successfully
transduce RPE and photoreceptor cells. However due to toxicity,
immunogenicity, and other safety concerns of adenoviral or lentiv-
iral vectors, AAV-based vectors quickly became a clear leader in the
race for retinal gene therapy (reviewed in Bainbridge, Tan, & Ali,
2006).
The next few years saw a surge in retinal gene transfer studies
where several rodent and large animal models were shown to be
amenable to histological and functional rescue of RPE and photore-
ceptor layers after AAV transgene delivery (reviewed in Buch,
Bainbridge, & Ali, 2008; Dalkara & Sahel, 2014; Dinculescu et al.,
2005; McClements & MacLaren, 2013; Petrs-Silva & Linden, 2014;
Smith, Bainbridge, & Ali, 2012). These studies were able to show
a widely heterogeneous behavior of AAV vectors ranging from dif-
fering retinal tropism amongst serotypes, route of vector delivery,
timing of injection and transduction efﬁciencies (Surace &
Auricchio, 2008). More recently technological advances have also
help improve gene delivery to the retina; continual discovery of
new serotypes and controlled mutations of capsid residues have
dramatically increased retinal transduction patterns (Petrs-Silva
& Linden, 2013; Vandenberghe & Auricchio, 2012) and a better
understanding of the kinetics of subretinal AAV delivery have also
aided in better study design and therefore more efﬁcient gene
transfer to the retina (Boye et al., 2012; Sarra et al., 2002;
Vandenberghe et al., 2011, 2013). However translating the results
from preclinical animal model studies to the clinic has proven dif-
ﬁcult and slow due to biological limitations imposed by the current
technologies or disease process, the lengthy, expensive, and com-
plex path of bringing a complex biologic to a clinical trial, and
the fact that many of these individual inherited retinal disorders
are extremely rare. Table 1 documents those efforts that success-
fully navigate this translational path, and shows a summary of cur-
rent ongoing trials for retinal disorders. With hundreds of disease
Table 1
Currently active clinical trials for inherited retinal dystrophies and age-related macular degeneration.
Disease Gene Coded protein Expression Frequency Vector
platform
Delivery Locations ClinicalTrials.gov ID
Active clinical trials
LCA2 RPE65 RPE-speciﬁc 65 kDa
protein






Choroideremia CHM Rab escort protein 1
(REP-1)
Ubiquitous 1:50,000 AAV2/2 SR UK,
Canada
NCT01461213; NCT02077361
Wet AMD FLT1 FMS-like tyrosine
kinase 1











SR USA NCT01301443; NCT01678872




















ArRP MERTK Mer receptor tyrosine
kinase
RPE Very rare AAV2/2 SR Saudi
Arabia
NCT01482195
Abbreviations: LCA, Leber Congenital Amaurosis; USH1B, Usher syndrome type 1b; ArRP, Autosomal recessive Retinitis Pigmentosa; RPE, retinal pigment epithelium, PR,
photoreceptors; RGC, retinal ganglion cells; SR, subretinal; IVT, intravitreal.
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which preclinical proof-of-concept rescue through gene augmenta-
tion therapy has been established, and the pivotal ﬁrst steps in
clinical demonstrations of efﬁcacy and safety shown, the question
remains on how the ﬁeld can bring therapies to the clinic for many
more of these often indications that individually often affect only
relatively small populations.2.2. Gene-independent treatment paradigms
The primary concept of optogenetics relies on the possibility of
delivering light-sensitive molecules to a retina where degeneration
is so advanced that all other therapies like gene replacement and
stem cell therapy are past their optimal window for treatment
and therefore might prove inefﬁcient. A non-endogenous light sen-
sitive molecule could then be targeted to what surviving cells are
remaining, and therefore not susceptible to the degeneration, but
are naturally incapable of responding to light stimulus. For this
approach to be successful there is a need for a good light-sensing
molecule that ideally does not require the presence of a detachable
chromophore-activating G-protein cascade, as is the case with
some opsin pigments, since the cells usually targeted in optogenet-
ics approaches are incapable of metabolising and recycling chro-
mophores. The answer to this was found in bacteria where
rhodopsin-like molecules, through reversible photoisomerization
of their chromophore group can directly generate ion movement
through the membrane creating an electrical signal in response
to light stimulation (Oesterhelt, 1998).
The ﬁrst study to use an optogenetic approach to restore light-
evoked response to the degenerate retina was published in 2006 by
Bi and Colleagues who showed that AAV2/2-based delivery of a
microbial-type rhodopsin called channelrhodopsin-2 (ChR2) to
the neurons of the mouse inner nuclear retinal layer was capable
of successfully generating light-evoked voltage responses of
ChR2-expressing retinal neurons, both at the retinal and cortical
levels, to retinal light stimulation in the rd1 mouse (Bi et al.,
2006). Since the publication of this ﬁrst study, many investigators
have been compelled by the power of bringing the technology of
gene therapy together with that of optogenetics to restore light
sensitivity and visual function to the retina in the blind. Othershave extensively reviewed this approach, and highlighted the
reﬁnements and advances that will be necessary to safely achieve
this ambitious approach in restoring clinically meaningful visual
perception (Busskamp et al., 2012; Cepko, 2010).
Other gene-independent treatments that have used to success-
fully prevent photoreceptors cell loss include retinal delivery of
neurotrophic factors during retinal degeneration. The rationales
behind these studies aim at prolonging photoreceptors survival
and therefore generating a better window for vector gene-delivery
treatments but also include the premise that survival of rod photo-
receptors will also prolong cone survival from secondary death
mechanisms. The best results have been achieved using AAV-deliv-
ered ciliary neurotrophic factor (CNTF), basic ﬁbroblast growth fac-
tor (FGF) and glial cell–derived neurotrophic factor (GDNF) (Bok
et al., 2002; Buch et al., 2006; Komaromy et al., 2013; Lau et al.,
2000; Liang et al., 2001; McGee Sanftner et al., 2001). However
the use of CNTF to prevent retinal degeneration has proven contro-
versial since some studies have shown an adverse and/or dose-
dependent effect (Bok et al., 2002; Buch et al., 2006; Liang et al.,
2001) and clinical trials using intraocular implant-delivered CNTF
in RP patients has reported no therapeutic improvement (Birch
et al., 2013).3. Technological innovation for current hurdles
3.1. Improving delivery and surgical access
In most active clinical studies the therapeutic vector is deliv-
ered by a subretinal injection (SR). This approach relies on the infu-
sion of vector in a virtual space between the outer nuclear layer
and RPE through the generation of an iatrogenic retinal detach-
ment. This unorthodox surgical intervention however has been
key to the success of retinal gene therapy efforts, particularly those
targeting ONL and RPE; vector is positioned in close proximity of
relevant therapeutic target cells, remains in a contained space
not subject to signiﬁcant dilution or biodistribution, and in preclin-
ical models has been shown to be far superior in terms of efﬁciency
as compared to any other route of administration. Surgically, ﬁrst
the vitreous is removed via a three-port pars plana vitrectomy.
Next, a subretinal cannula is inserted below the retina where the
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Bainbridge et al., 2008; Maguire et al., 2008). This translates to a
focal area of treatment (referred to as the bleb) and allows posi-
tioning of the vector e.g. centrally or peripherally. Remarkably,
from experience in small and large animal models, the bleb
resolves relatively fast and leads to a quiet retina in less than a
few days in most cases. Indeed the procedure was found to be
overall safe in humans too in the RPE65 clinical trials where in
most patients no surgical adverse effects were reported
(Bainbridge et al., 2008; Cideciyan et al., 2009; Hauswirth et al.,
2008; Maguire et al., 2008, 2009). The adverse effects that were
observed occurred in the immediate postoperative days and
included retinal detachments, foveal thinning, macular holes, cho-
roidal effusions and ocular hypo- and hypertension (Jacobson et al.,
2012; Maguire et al., 2008). Of these, only the macular hole (one
patient) Maguire et al., 2008 and one case of persistent choroidal
effusions (Jacobson et al., 2012) were not resolved after 30–60 days
post-surgery. While overall subretinal injection appears to be well
tolerated, they are complex with inherent variables from patient to
patient, lengthy, and require unique and expert surgical skill.
Although the majority of the clinical trials data show no detrimen-
tal effect of the surgery on the retina, one study reported that two
out of ﬁve patients where the injected area included the fovea
showed foveal thinning at early postoperative time points
(Jacobson et al., 2012). This was concluded to be due to damage
from the surgical retinal detachment as opposed to foveal thinning
at later time points as a consequence of natural progression of dis-
ease (Jacobson et al., 2012).
Although most studies do not report retinal thinning and major
complication due to the surgical procedure (Bainbridge et al., 2008;
Bennett et al., 2012; MacLaren et al., 2014), this effect, or lack
thereof, could be disease-related and therefore dependent on
how preserved and stable are the interactions between RPE and
photoreceptor layers in each case. Despite the promising evidence
from the Choroideremia trial where patients with near normal
visual acuity underwent the surgical procedure without signiﬁcant
loss of acuity (MacLaren et al., 2014), it still remains unclear if this
is related to the speciﬁc genetic defect of these patients or just
related to retinal and foveal thickness at the time of surgery. There-
fore, this might become an increasingly vexing question with the
possibility of pre-treatment of genetic retinal defects; how will-
ingly would asymptomatic patients accept a treatment that results
in retinal damage and potential loss of vision acuity to save them
from more severe damage in the future? This has generated efforts
towards the development and optimization of a less invasive alter-
native to deliver gene therapy vectors to the eye and the alterna-
tive delivery method, which is less invasive and would not
require a retinal detachment, would be through intravitreal injec-
tions (IVT). With this procedure the gene delivery agent can be
injected into the vitreous of the patients and diffused into the ret-
inal layers from within the vitreous cavity bypassing several of the
risks involved with a subretinal injection.
Regardless of the individual risks of each type of surgery, the
most important difference between the two methods of gene deliv-
ery probably lies in their vector transduction and diffusion pattern.
Through a subretinal injection each individual cell transduced in
the subretinal space will be exposed to varying levels of the ther-
apeutic agent; cells in the center of the bleb will be transduced
by a much higher number of particles than the ones in the periph-
ery. This would be advantageous, for example, when targeting dis-
eases that affect the macula, where a focal high dose delivery
would increase the chances of rescue. However for disorders where
widespread retinal degeneration is seen, like in RP patients for
example, an intravitreal approach could offer a more appropriate
delivery of the vector, targeting a larger population of cells with
more uniform transduction levels. This method would ideally offera much wider, pan-retinal homogeneous transduction area.
Whether better vision restoration would be achieved via a concen-
trated focal versus a diluted widespread delivery remains a very
interesting discussion point that still needs to be evaluated on sev-
eral different parameters to provide an answer.
However, transduction efﬁcacy of rAAV vectors delivered from
the vitreous have had limited success in the past, with AAV2/2
achieving the highest number of transduced retinal cells in mouse,
dogs and non-human primates compared to several other sero-
types (Hellstrom et al., 2009; Yin et al., 2011). However, the imped-
iment for successful transduction of the retinal cell layers via
intravitreal injections are thought to be the vitreous jelly, the phys-
ical barrier created by the inner limiting membrane (ILM) and the
complex tangle of different cells and processes that form the vitre-
ous and inner retina (Hellstrom et al., 2009). Nevertheless recent
efforts to improve cell transduced after intravitreal injection have
been met with encouraging success. Recently a study led by Drs.
Schaffer and Flannery at the University of California, Berkeley, used
an in vivo-directed evolution approach to select, from a genetically
engineered capsid AAV library, variants capsids that were able to
transduced different retinal cell types via an intravitreal injection
(Dalkara et al., 2013; Klimczak et al., 2009). After a few rounds of
in vivo selection, they were able to select AAV capsids that showed
a high transduction efﬁciency of different retinal layers using
either a ubiquitous or rod-speciﬁc promoter (Dalkara et al., 2013;
Klimczak et al., 2009). The best AAV variants from these studies,
7m8 and ShH10, have already been used in subsequent studies
demonstrating effective gene delivery and functional rescue of
the retinoschisin protein-deﬁcient Rs1h/ mouse model of X-
linked retinoschisis (Byrne et al., 2014). Other studies using intra-
vitreal delivery to target retinal cells have used targeted mutations
of AAV capsid residues showing that a ﬁve mutation AAV2 capsid
can efﬁciently target photoreceptors in the mouse retina (Kay
et al., 2013). Data from these studies demonstrates increased efﬁ-
ciencies of retinal targeting from this clinically more attractive
route of administration in mice, however experience in larger ani-
mal models have been less encouraging, likely due to the barriers
to transduction that are more pronounced in larger eyes.
3.2. Size matters
As demonstrated by the results from the clinical trials and years
of pre-clinical research, safety and efﬁcacy has made AAV the vec-
tor of choice for gene augmentation in retina. However, a major
shortcoming is its small genome size, restricting the amount of
the packaged transgene to around 4.7 kilobases (Srivastava,
Lusby, & Berns, 1983). This small genome capacity thus becomes
a limiting factor for devising current gene replacement therapy
for many important causes of disease, such as mutations in the
CEP290, MYO7A or RP1 genes, which have cDNAs signiﬁcantly lar-
ger than the carrying capacity of AAV. Even in the cases of smaller
genes, the use of speciﬁc promoters and other minimal regulatory
elements is often necessary, resulting in compromises on trans-
gene expression levels and dynamics of regulation. Even though
larger packaging viruses and naked DNA delivery systems like
nanoparticles could provide an alternative approach and circum-
vent this problem, no other vector system has been deﬁned that
rivals the efﬁciency of gene transfer and the safety proﬁle of AAV.
Therefore the pursuit to increase the carrying capacity of the
AAV has generated considerable interest from the scientiﬁc com-
munity recently. Based on the capacity of AAV circular genomes
to concatamerize via intermolecular recombination (Yang et al.,
1999), Yan and colleagues were the ﬁrst to demonstrate that two
independent Trans-splicing rAAV vectors encoding non-overlap-
ping segments of the large erythropoietin (Epo) gene and
intron donor and acceptor sites were able to express protein at
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later expanded to include other strategies for gene reconstitution
like sequence overlap (Duan, Yue, & Engelhardt, 2001), a triple
Trans-splicing (Koo et al., 2014) and a hybrid of Trans-splicing
and sequence overlap with the hybrid strategy showing the highest
efﬁciency (Ghosh et al., 2008). Also subsequent studies have shown
protein expression and functional in vivo rescue after reconstitu-
tion of other large genes like dystrophin (Zhang & Duan, 2012;
Zhang et al., 2013) and dysferlin (Grose et al., 2012; Lostal et al.,
2010).
There have also been some tentative efforts to use these dual
AAV strategies to develop gene replacement therapy for some
cases of retinal degeneration, mainly those caused by mutations
in ABCA4, CEP290 and MYO7A (Colella et al., 2014; Dyka et al.,
2014; Lopes et al., 2013). Recessive mutations in MYO7A are
responsible for around half of all Usher syndrome type 1 cases
but with a cDNA of almost 7 kb it has remained an elusive candi-
date for gene replacement therapy. Initial results for MYO7A gene
delivery in the retina showed that AAV2 or AAV5 encoding the
full-length gene was more efﬁcient both in vitro and in vivo when
compared to a dual vector overlap approach (Lopes et al., 2013).
Although certain serotypes were reported to be able to package
genomes up to 8 kb (Allocca et al., 2008), follow-up studies
revealed that the resulting transgene activity was actually due to
separately packaged heterogeneous population of fragmented
AAV genomes reconstituting the full-length transgene (Dong,
Nakai, & Xiao, 2010; Kapranov et al., 2012; Lai, Yue, & Duan,
2010). Although Lopes and colleagues do suggest that MYO7A
expression is probably due to successful recombination of overlap-
ping fragments, they are unable to explain the low reconstitution
rate of the dual overlap AAV strategy (Lopes et al., 2013). A recent
paper by Trapani et al. has shed some light into this issue by show-
ing that mouse and pig photoreceptors can be efﬁciently trans-
duced by trans-splicing and hybrid dual AAVs but not by
overlapping vectors (Trapani et al., 2014). This was again con-
ﬁrmed later in another study when MYO7A levels in mouse retinas
injected subretinally with either overlapping or hybrid dual AAVs
were only detectable, by western blotting, with the hybrid
approach (Dyka et al., 2014).
Although in vivo retinal levels of protein after subretinal admin-
istration of dual trans-splice or hybrid AAVs has been shown to be
around 20% of endogenous levels (Trapani et al., 2014), dual AAV
vector approaches have not gained major popularity since circum-
venting the AAV carrying capacity problem in this manner severely
impacts transgene expression efﬁciencies and it is still unclear why
fragment reconstitution levels are so inefﬁcient.
3.3. To AAV, or not to AAV
Regardless of the extremely successful recent history of AAV-
mediated gene therapy for several ocular disorders, the current
technologies still limit translation for many indications to which
we have not yet found solutions for. One of the main restrictions
of AAV-based vectors is the limited size of the therapeutic cargo
it can package, and is often the primary reasons to consider alter-
native delivery strategies. AAV is generally seen as of low immuno-
genic potential, certainly compared to adenoviral vectors, however
the preclinical lead up of Genzyme’s wet AMD AAV2 clinical study
encountered moderate, self-limiting yet long lasting inﬂammation
in the vitreous (Maclachlan et al., 2011). This may or may not be a
function of the fact that AAV is endemic in primates, and an AAV
vector dosing would elicit a memory response and/or encounter
pre-existing immunity. The latter was studied in a sampling of vit-
reous ﬂuid in which low level neutralizing anti-AAV antibodies
were detected that could interfere with retinal AAV gene transfer
(Cheng et al., 2013). Despite the overwhelming number ofAAV-based studies for gene therapy in the eye, lentiviral vectors
offer an attractive alternative due to their ability to transduce div-
ing and non-diving cells stably and have a much larger genome
packaging capacity compared to AAV vectors. The most widely
used vectors currently are derived from the human/simian immu-
nodeﬁciency virus (HIV/SIV) or the equine infectious anemia virus
(EIAV). Besides their ability to carry larger genome they can also
undergo a pseudotype process where envelope proteins can be
exchanged with that of other viruses therefore modifying its tro-
pism (reviewed in Bischof & Cornetta, 2010).
Initial vectors derived from retroviruses were only able to trans-
duce dividing cells and were therefore very inefﬁcient on post-
mitotic adult photoreceptors and RPE cells, restricting its applica-
tions to ex vivo gene transfer (Dunaief et al., 1995; Kido et al.,
1996). The later development of a modiﬁed replication-deﬁcient
HIV-derived retroviral vector allowed the transduction of non-
dividing cells (Blomer et al., 1996) and was subsequently shown
to successfully target photoreceptors and RPE cells, corneal endo-
thelium and trabecular meshwork (Bainbridge et al., 2001;
Lipinski et al., 2014; Miyoshi et al., 1997). However the percentage
of transduced mouse photoreceptors after lentiviral gene delivery
still remains higher in newborn retinas compared to adult mice
(Kostic et al., 2003). One explanation was offered by Gruter et al.
(2005) who showed improved photoreceptor transduction after
treatment with chondroitinase or neurominidase, therefore sug-
gesting that a physical barrier could be preventing virus diffusion
through the retina. Despite the drawbacks of lentiviral-based vec-
tors for inherited retinal disorders, there are currently three ongo-
ing clinical trials using EIAV-based vectors, two to deliver large
genes to photoreceptors subretinally and the other encoding the
genes for two angiostatic proteins for intravitreal delivery (see Sec-
tions 1.3.1 and 1.3.2). The outcome of these trials will be closely
followed by the scientiﬁc community since they might provide
alternative platforms for gene therapy for vision loss.
A promising new approach that appears to be able to overcome
some of these issues is the use of nanoparticles to deliver therapeu-
tic agents to target tissues. These non-viral delivery systems may
offer a less invasive, low immunogenic and inﬂammatory response
and can package plasmids up to 20 kb, therefore holding great
potential as a future therapeutic option. They mainly involve cat-
ionic lipids or polymers which then form lipoplexes or polyplexes
around a DNA molecule and have been shown to successfully deli-
ver DNA particles to different ocular tissues (del Pozo-Rodriguez
et al., 2013; Han et al., 2012; Koirala, Conley, & Naash, 2013;
Koirala et al., 2013; Kompella et al., 2013). However as a tool for
ocular gene therapy these polymeric vectors still need to overcome
several issues prior to translational applications. Some of these
include permeation barriers like the vitreous and the blood-retinal
barriers, low efﬁciency, short half-life and transient gene expres-
sion and non-targeted delivery (reviewed in Diebold & Calonge,
2010; Tamboli, Mishra, & Mitrat, 2011). Non-viral vectors do hold
future potential for becoming a viable option for ocular gene ther-
apy but further studies into the issues mentioned above are
required before serious consideration in a clinical setting.4. Looking ahead
In vivo gene therapy has been pursued for several decades, and
now recently has reached a point where patient beneﬁt has been
demonstrated in a discreet number of retinal clinical trials for
two blinding disorders. The validation of this potentially powerful
approach has generated excitement to develop more gene treat-
ments for inherited forms of blindness. In fact, using the same
technology and lessons learned from the ﬁrst pivotal studies, it
has been proposed to build a platform of which all components
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gene cargo is exchanged depending on the indications (O’Reilly
et al., 2013). It will indeed be necessary to streamline the develop-
ment and regulatory hurdles for these types of therapies if ever the
ﬁeld wants to target therapeutics to the multitude retinal dystro-
phies. This is particularly true for those very rare indications for
which gene therapy has the potential to be beneﬁcial, however
due to the limited prevalence, the costly pursuit of building and
developing a treatment is economically difﬁcult to ﬁnd traction
for. To build a platform as described above, progress has to be
made in several aspects of this intricate ﬁeld of converging exper-
tise, some of which are addressed above. In addition to working out
methods and technologies to improve the safety and efﬁcacy of
this still experimental approach, it is becoming increasingly impor-
tant to ﬁnd better ways to capture accurately and with great sen-
sitivity the therapeutic beneﬁt that a gene therapy may bring to
the patient. This will require extensive natural history studies for
each indication to map, and ultimately predict, disease progres-
sion, validation of clinical endpoints (including imaging modalities
and biomarkers), and with those data at hand, an effort to convince
regulatory agencies that these can measure a meaningful beneﬁt to
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